Modified-Release NifedipineA Review of the Use of Modified-Release Formulations in the Treatment of Hypertension and Angina Pectoris

[1] Sorkin EM(1985)Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders Drugs 30 182-274

[2] Clissold SP(1996)The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties Clin Pharmacokinet 30 28-51

[3] Brogden RN(2005)Persistence with antihypertensives related to formulation: the case of nifedipine Ann Pharmacother 39 237-42

[4] Grundy JS(2003)2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension J Hypertens 21 1983-92

[5] Foster RT(1991)Sustained release nifedipine formulations; an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders Drugs 41 737-79

[6] Breekveldt-Postma NS(1995)Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris Drugs 50 495-512

[7] Herings RMC(1995)Arterial hemodynamics in human hypertension: effects of the calcium channel antagonist nifedipine Hypertension 25 1326-32

[8] Whitworth JA(2001)Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial Circulation 104 1248-54

[9] Murdoch D(1992)Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine Am J Cardiol 70 468-73

[10] Brogden RN(1998)Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients Blood Press 7 160-9

[1] Sorkin EM(1985)Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders Drugs 30 182-274

[2] Clissold SP(1996)The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties Clin Pharmacokinet 30 28-51

[3] Brogden RN(2005)Persistence with antihypertensives related to formulation: the case of nifedipine Ann Pharmacother 39 237-42

[4] Grundy JS(2003)2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension J Hypertens 21 1983-92

[5] Foster RT(1991)Sustained release nifedipine formulations; an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders Drugs 41 737-79

[6] Breekveldt-Postma NS(1995)Nifedipine gastrointestinal therapeutic system (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris Drugs 50 495-512

[7] Herings RMC(1995)Arterial hemodynamics in human hypertension: effects of the calcium channel antagonist nifedipine Hypertension 25 1326-32

[8] Whitworth JA(2001)Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial Circulation 104 1248-54

[9] Murdoch D(1992)Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine Am J Cardiol 70 468-73

[10] Brogden RN(1998)Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients Blood Press 7 160-9